Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism CD11b activators(integrin subunit alpha M activators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | US | 27 Apr 2020 | |
Solid tumor | Preclinical | GB | 27 Apr 2020 | |
Gastroesophageal junction adenocarcinoma | Preclinical | GB | 13 Aug 2019 | |
Gastroesophageal junction adenocarcinoma | Preclinical | GB | 13 Aug 2019 | |
Gastroesophageal junction adenocarcinoma | Preclinical | US | 13 Aug 2019 | |
Gastroesophageal junction adenocarcinoma | Preclinical | US | 13 Aug 2019 | |
Renal Cell Carcinoma | Preclinical | US | 13 Aug 2019 | |
Renal Cell Carcinoma | Preclinical | GB | 13 Aug 2019 | |
Renal Cell Carcinoma | Preclinical | US | 13 Aug 2019 | |
Renal Cell Carcinoma | Preclinical | GB | 13 Aug 2019 |
Phase 1 | 45 | (dcbtwdnzrf) = No DLTs were reported. xwyaktwufi (uwwxfacxah ) View more | Positive | 20 May 2021 | |||